Oncology · ImmunotherapyTrial Updateclinicalmid-term

Phase II Trial of Nivolumab and Ipilimumab in dMMR Recurrent Endometrial Carcinoma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/15/2026, 6:02:46 AM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase II trial of nivolumab combined with ipilimumab in dMMR recurrent endometrial carcinoma could significantly alter treatment protocols in this niche oncology segment. Positive trial outcomes may enhance competitive positioning for companies involved in immunotherapy, necessitating close monitoring of results. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 22 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should monitor trial outcomes as positive results could lead to new treatment protocols and market opportunities in dMMR cancers. The strongest clinical anchor is Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (ClinicalTrials.gov), entity match (nivolumab); patient population match (recurrent). In Oncology · Immunotherapy, 3 regulatory and 5 competitive items passed relevance filtering for Nivolumab.

Competitive Pressure

The most relevant competitive pressure comes from Divarasib Study Targets KRAS G12C-Positive NSCLC Post-Chemoimmunotherapy (Humanexa Signals) — entity match (nivolumab). Secondary pressure from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC).

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. If the trial demonstrates efficacy, it may lead to new treatment approvals and label expansions, impacting compliance and market access strategies.

Key Risks

Elevated medium regulatory exposure for Nivolumab could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful trial results could lead to new market opportunities and potentially increase market share for the combination therapy in the immunotherapy landscape for endometrial cancer.
Upside for Nivolumab may improve if Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · KRAS G12C-Positive Non-Small Cell Lung Cancer · Trial Update · This trial positions divarasib as a potential alternative to established therapies like pembrolizumab and nivolumab for KRAS G12C-positive NSCLC.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
Upside for Nivolumab may improve if Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and overall survival data from the trial.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govhigh relevance
Entity match (nivolumab); Patient population match (recurrent)
FDA document
View source
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (recurrent)
FDA document
View source
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Divarasib Study Targets KRAS G12C-Positive NSCLC Post-Chemoimmunotherapy
Humanexa Signalshigh relevance
Entity match (nivolumab)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Immune Profiling in dMMR/MSI-H CRC Reveals Prognostic Insights and Immunotherapeutic Potential
Humanexa Signalsmedium relevance
Moderate corpus alignment

Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence treatment.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Nivolumab
Ipilimumab
dMMR recurrent endometrial carcinoma
National Cancer Institute
NRG Oncology

Commercial impact

medium

Successful trial results could lead to new market opportunities and potentially increase market share for the combination therapy in the immunotherapy landscape for endometrial cancer.

Regulatory impact

medium

If the trial demonstrates efficacy, it may lead to new treatment approvals and label expansions, impacting compliance and market access strategies.

What to watch

Key milestones include interim results and overall survival data from the trial.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.